Investigation of cross-opsonic effect leads to the discovery of PPIase-domain containing protein vaccine candidate to prevent infections by Gram-positive ESKAPE pathogens
BMC Microbiology · 2024
DOI: 10.1186/s12866-024-03427-w ↗Kurz gefasst
Fachartikel in der Zeitschrift BMC Microbiology, 2024. Verfasst von Océane Sadones und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of pediatric infectious disease, Hauner children's hospital, LMU, Munich, Germany. sadonesoceane@gmail.com. Hauptthemen laut MEDLINE: Staphylococcus aureus, Enterococcus faecium, Bacterial Proteins, Peptidylprolyl Isomerase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.
Abstract (Originalsprache)
Background
Enterococcus faecium and Staphylococcus aureus are the Gram-positive pathogens of the ESKAPE group, known to represent a great threat to human health due to their high virulence and multiple resistances to antibiotics. Combined, enterococci and S. aureus account for 26% of healthcare-associated infections and are the most common organisms responsible for blood stream infections. We previously showed that the peptidyl-prolyl cis/trans isomerase (PPIase) PpiC of E. faecium elicits the production of specific, opsonic, and protective antibodies that are effective against several strains of E. faecium and E. faecalis . Due to the ubiquitous characteristics of PPIases and their essential function within Gram-positive cells, we hypothesized a potential cross-reactive effect of anti-PpiC antibodies.
Results
Opsonophagocytic assays combined with bioinformatics led to the identification of the foldase protein PrsA as a new potential vaccine antigen in S. aureus . We show that PrsA is a stable dimeric protein able to elicit opsonic antibodies against the S. aureus strain MW2, as well as cross-binding and cross-opsonic in several S. aureus , E. faecium and E. faecalis strains.
Conclusions
Given the multiple antibiotic resistances S. aureus and enterococci present, finding preventive strategies is essential to fight those two nosocomial pathogens. The study shows the potential of PrsA as an antigen to use in vaccine formulation against the two dangerous Gram-positive ESKAPE bacteria. Our findings support the idea that PPIases should be further investigated as vaccine targets in the frame of pan-vaccinomics strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of pediatric infectious disease, Hauner children's hospital, LMU, Munich, Germany. sadonesoceane@gmail.com.
- Institute of Biostructures and Bioimaging, Italian Research Council (CNR), Naples, Italy.
- Division of pediatric infectious disease, Hauner children's hospital, LMU, Munich, Germany.
- Division of pediatric infectious disease, Hauner children's hospital, LMU, Munich, Germany. johannes.huebner@med.uni-muenchen.de.
Förderung
- Klinikum der Universität München
Zitieren
APA
Sadones, O., Kramarska, E., Laverde, D., Berisio, R., Huebner, J., & Romero-Saavedra, F. (2024). Investigation of cross-opsonic effect leads to the discovery of PPIase-domain containing protein vaccine candidate to prevent infections by Gram-positive ESKAPE pathogens. BMC Microbiology. https://doi.org/10.1186/s12866-024-03427-w
Vancouver
Sadones O, Kramarska E, Laverde D, Berisio R, Huebner J, Romero-Saavedra F. Investigation of cross-opsonic effect leads to the discovery of PPIase-domain containing protein vaccine candidate to prevent infections by Gram-positive ESKAPE pathogens. BMC Microbiology. 2024. doi:10.1186/s12866-024-03427-w
BibTeX
@article{Sadones2024,
author = {Sadones, Océane and Kramarska, Eliza and Laverde, Diana and Berisio, Rita and Huebner, Johannes and Romero-Saavedra, Felipe},
title = {Investigation of cross-opsonic effect leads to the discovery of PPIase-domain containing protein vaccine candidate to prevent infections by Gram-positive ESKAPE pathogens},
journal = {BMC Microbiology},
year = {2024},
doi = {10.1186/s12866-024-03427-w}
}
EUVIMED